SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Alembic Pharmaceutical reports 86% fall in Q4 consolidated net profit

04 May 2022 Evaluate

Alembic Pharmaceutical has reported results for fourth quarter and year ended March 31, 2022.

The company has reported a rise of 8.77% in its net profit at Rs 251.37 crore for the quarter under review as compared to Rs 231.11 crore for the same quarter in the previous year. Total income of the company increased by 11.33% at Rs 1315.91 crore for Q4FY22 as compared Rs 1181.98 crore for the corresponding quarter previous year.

On the consolidated basis, the company has reported fall of 85.86% in its net profit at Rs 35.46 crore for the quarter under review as compared to Rs 250.70 crore for the same quarter in the previous year. However, total income of the company increased by 9.21% at Rs 1426.01 crore for Q4FY22 as compared Rs 1305.80 crore for the corresponding quarter previous year.

For the year ended March 31, 2022, the company has reported a fall of 32.45% in its net profit at Rs 794 crore as compared to Rs 1175.39 crore for the previous year. Total income of the company decreased by 1.72% at Rs 5046.58 crore for year under review as compared to Rs 5134.96 crore for year ended March 31, 2021.

For the year ended March 31, 2022, on the consolidated basis, the company has reported a fall of 53.68% in its net profit at Rs 545.68 crore as compared to Rs 1178.11 crore for the previous year. Total income of the company decreased by 2.26% at Rs 5356.25 crore for year under review as compared to Rs 5480.42 crore for year ended March 31, 2021.

Alembic Pharma Share Price

785.40 8.05 (1.04%)
08-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1847.30
Dr. Reddys Lab 1293.25
Cipla 1347.70
Zydus Lifesciences 938.90
Lupin 2377.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×